<div id="readability-page-1"><p>In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics, with a price target of <span id="expert-recommendation-target">$8.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Newman covers the Healthcare sector, focusing on stocks such as Regeneron, Arcellx Inc, and Delcath Systems. According to TipRanks, Newman has an average return of <span>-1.4%</span> and a 37.37% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Marker Therapeutics is a Moderate Buy with an average price target of $8.00.</p></div>

MRKR

<p>Canaccord Genuity's John Newman maintains a Buy rating on Marker Therapeutics with a price target of $8.00. Newman, who covers the Healthcare sector, has an average return of -1.4% and a 37.37% success rate. The analyst consensus on Marker Therapeutics is a Moderate Buy with an average price target of $8.00.</p>

Canaccord Genuity Keeps Their Buy Rating on Marker Therapeutics (MRKR)